Man Group
LAB icon

Man Group’s Standard BioTools LAB Stock Holding History

Man Group’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,913
Closed -$22.9K – 2094
2024
Q2 		$22.9K Sell
12,913
-297,691
-96% -$728K ﹤0.01% 1988
2024
Q1 		$842K Buy
310,604
+112,424
+57% +$271K ﹤0.01% 1612
2023
Q4 		$438K Buy
+198,180
New +$423K ﹤0.01% 1718
2022
Q1 		– Sell
-21,100
Closed -$83K – 2272
2021
Q4 		$83K Sell
21,100
-35,800
-63% -$168K ﹤0.01% 1889
2021
Q3 		$375K Buy
+56,900
New +$374K ﹤0.01% 1600
2019
Q2 		– Sell
-13,295
Closed -$177K – 1948
2019
Q1 		$177K Buy
+13,295
New +$140K ﹤0.01% 1888

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Man Group's LAB Position: Q3 2024 in Review

Man Group sold out of Standard BioTools (LAB) in Q3 2024, closing a stake of 12,913 shares — an estimated $22.9K sold.

Man Group first reported a position in LAB in Q1 2019 and held it in 6 quarters. The position peaked at $842K in Q1 2024. 141 funds tracked by Wall St. Rank hold LAB as of Q3 2024.

  • Man Group reported no remaining Standard BioTools position as of Q3 2024 after selling out during the quarter.
  • Man Group sold 12,913 Standard BioTools shares in Q3 2024, an estimated $22.9K.
  • Man Group first reported a position in Standard BioTools in Q1 2019 and held it in 6 quarters.
  • Man Group's Standard BioTools position peaked at $842K in Q1 2024.
  • 141 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2024.

Based on Man Group's 13F filing for Q3 2024, filed 14 Nov 2024.